Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Teva Pharma Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (156)
ARTG (126)
Prescription medicine registration (23)
Australian Public Assessment Report (AusPAR) (7)
Prescription medicine decision summary (3)
Section 14, TGO91 consent (2)
Designation or determination (1)

Date

2024 (120)
2023 (16)
2022 (13)
2021 (68)
2020 (23)
2019 (11)
2018 (6)
2017 (8)
2016 (25)
2015 (9)
2012 (2)
2011 (4)
2010 (1)
2006 (3)
2002 (7)
1995 (2)

Results for "[search-keyword]"

Search

Sponsor content

318 result(s) found, displaying 231 to 240

CON-TGO91-163 - Teva Pharma Australia Pty Ltd

4 August 2020

Section 14, TGO91 consent

Product(s) approved for Supply with noncompliant labelling.
BIRESP SPIROMAX, DUORESP SPIROMAX (Teva Pharma Australia Pty Ltd)

30 April 2020

Prescription medicine registration

Active ingredients: budesonide; formoterol (eformoterol) fumarate dihydrate.
TEVAPEZIL donepezil hydrochloride (as monohydrate) 10 mg film coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PREXTEVA olanzapine 2.5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PREXTEVA olanzapine 5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PREXTEVA olanzapine 7.5 mg film-coated tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
CINQAERO reslizumab 100 mg/10 mL concentrated solution for intraveous infusion vial Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
PREXTEVA ODT olanzapine 20 mg orally disintegrating tablet blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
EXOREX PENETRATING EMULSION PSORIASIS MEDICATION gel bottle Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd
TEVXELIN capecitabine 150mg film-coated tablets blister pack Cancelled under Section 30(1)(c) of the Act

19 February 2020

Cancellation by sponsor

Requested by Teva Pharma Australia Pty Ltd

Pages

First page
Previous page
…
Page 20
Page 21
Page 22
Page 23
Current page 24
Page 25
Page 26
Page 27
Page 28
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.